Sangamo Therapeutics - SGMO Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.00
  • Forecasted Upside: 109.21 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.78
▼ -0.12 (-2.45%)

This chart shows the closing price for SGMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sangamo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGMO

Analyst Price Target is $10.00
▲ +109.21% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Sangamo Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $19.00 and a low forecast of $5.00. The average price target represents a 109.21% upside from the last price of $4.78.

This chart shows the closing price for SGMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Sangamo Therapeutics. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/13/2022WedbushReiterated RatingNeutral$5.00Medium
5/6/2022WedbushReiterated RatingNeutralHigh
4/5/2022Truist FinancialLower TargetBuy$23.00 ➝ $19.00Low
2/27/2022WedbushReiterated RatingHold$10.00Medium
1/7/2022WedbushReiterated RatingHold$10.00High
1/6/2022Stifel NicolausLower TargetHold ➝ Hold$9.00 ➝ $6.00High
8/26/2021HC WainwrightInitiated CoverageBuy$25.00Medium
5/3/2021Royal Bank of CanadaInitiated CoverageOutperform$22.00High
3/3/2021Wells Fargo & CompanyLower TargetOverweight$36.00 ➝ $29.00High
1/5/2021Stifel NicolausInitiated CoverageHold$16.00N/A
12/16/2020HC WainwrightReiterated RatingBuy$25.00Low
9/8/2020Bank of AmericaInitiated CoverageBuy$20.00Low
7/7/2020SunTrust BanksInitiated CoverageBuyHigh
6/22/2020HC WainwrightLower TargetBuy$16.00 ➝ $14.00Medium
6/19/2020WedbushReiterated RatingHold$11.00Medium
6/10/2020WedbushReiterated RatingHold$11.00High
3/4/2020WedbushReiterated RatingHold$10.00High
3/2/2020HC WainwrightReiterated RatingBuy$16.00High
12/23/2019HC WainwrightReiterated RatingBuy$16.00High
12/18/2019WedbushReiterated RatingHold$11.00Medium
12/11/2019WedbushReiterated RatingHold$11.00Low
12/9/2019CowenReiterated RatingBuyHigh
11/12/2019WedbushReiterated RatingHold$11.00Low
8/26/2019HC WainwrightInitiated CoverageBuy$16.00Medium
7/8/2019WedbushSet TargetHold$11.00Medium
6/23/2019WedbushSet TargetHold$11.00Medium
5/14/2019WedbushSet TargetHold$11.00Medium
3/10/2019WedbushSet TargetHold$10.00Medium
11/19/2018WedbushSet TargetHold$11.00Low
11/14/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$35.00 ➝ $11.00High
11/9/2018GuggenheimDowngradeBuy ➝ Neutral$18.00High
10/9/2018GuggenheimInitiated CoverageBuy ➝ Buy$18.00High
8/9/2018WedbushReiterated RatingHold$10.00High
7/24/2018WedbushReiterated RatingHold$9.00Medium
7/23/2018CowenReiterated RatingBuyLow
6/20/2018Bank of AmericaInitiated CoverageBuy$24.00High
3/13/2018WedbushReiterated RatingHold$8.00Medium
2/25/2018BarclaysReiterated RatingBuy$30.00Low
2/23/2018Jefferies Financial GroupReiterated RatingBuyLow
2/12/2018WedbushReiterated RatingNeutral$6.00High
1/3/2018Piper Jaffray CompaniesSet TargetBuy$25.00High
11/22/2017BarclaysInitiated CoverageOverweight$20.00N/A
11/15/2017WedbushReiterated RatingHold$6.00N/A
11/15/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$19.00N/A
10/13/2017Jefferies Financial GroupReiterated RatingBuy$18.00N/A
(Data available from 10/4/2017 forward)

News Sentiment Rating

-0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/3/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sangamo Therapeutics logo
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $4.78
Low: $4.67
High: $5.01

50 Day Range

MA: $5.32
Low: $4.27
High: $6.39

52 Week Range

Now: $4.78
Low: $3.12
High: $11.49

Volume

1,659,698 shs

Average Volume

1,576,016 shs

Market Capitalization

$748.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Sangamo Therapeutics?

The following equities research analysts have issued research reports on Sangamo Therapeutics in the last twelve months: Stifel Nicolaus, StockNews.com, Truist Financial Co., and Wedbush.
View the latest analyst ratings for SGMO.

What is the current price target for Sangamo Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Sangamo Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 109.2%. Truist Financial Co. has the highest price target set, predicting SGMO will reach $19.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $5.00 for Sangamo Therapeutics in the next year.
View the latest price targets for SGMO.

What is the current consensus analyst rating for Sangamo Therapeutics?

Sangamo Therapeutics currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SGMO, but not buy more shares or sell existing shares.
View the latest ratings for SGMO.

What other companies compete with Sangamo Therapeutics?

How do I contact Sangamo Therapeutics' investor relations team?

Sangamo Therapeutics' physical mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company's listed phone number is (510) 970-6000 and its investor relations email address is [email protected] The official website for Sangamo Therapeutics is www.sangamo.com. Learn More about contacing Sangamo Therapeutics investor relations.